Exploring approved weight loss options in 2026 While Retatrutide represents one of several next-generation weight loss drugs under investigation, licensed treatments are already available in the UK following clinical assessment
Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)
A 2.0 mg dose was approved in 2024 for additional glycaemic control
This is called energy compensation
These might include: Pregnancy test : Essential first step for any woman of reproductive age with menstrual changes Blood tests : To assess hormone levels (FSH, LH, oestradiol, prolactin, thyroid function) and full blood count if bleeding is heavy STI screening : Particularly for unexplained intermenstrual or postcoital bleeding Pelvic ultrasound : If structural causes need to be excluded Review of medication : To ensure no drug interactions or other contributing factors Keep a menstrual diary noting cycle length, flow heaviness, and any associated symptoms
Importantly, treatment with retatrutide not only resulted in robust weight reduction, but also in clear improvements in assessed cardiometabolic health measures